Skip to content

BCBS Arizona

Does BCBS Arizona cover Wegovy for Heart Disease Risk Reduction?

Yes. BCBS Arizona covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.

Policy on file; the document isn't available to view online yet.

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Approval: Wegovy for CV Risk Reduction

All of:

  • Age ≥ 45 years
  • BMI ≥ 27 kg/m2
  • Established cardiovascular disease (prior MI, prior ischemic or hemorrhagic stroke, or symptomatic PAD as defined below)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes (gestational diabetes excluded from this restriction)
  • Does NOT have NYHA Class IV heart failure
  • Where clinically appropriate, is on guideline-directed standard of care for CV condition (e.g., lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, ARNI)
  • Will be used as adjunct to a program supporting reduced calorie diet (≥ 500 kcal/day reduction) and ≥ 150 min/week activity
  • Prescribed by or in consultation with a Cardiologist
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Prior myocardial infarction
  • Prior ischemic or hemorrhagic stroke
  • Symptomatic PAD: intermittent claudication with ABI < 0.85 at rest
  • Symptomatic PAD: peripheral arterial revascularization procedure
  • Symptomatic PAD: amputation due to atherosclerotic disease

Continuation/Renewal: Wegovy for CV Risk Reduction

All of:

  • Continues to be seen by physician specializing in diagnosis or in consultation with a Cardiologist
  • Confirmed established cardiovascular disease (same qualifying events as initial)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes
  • Does NOT have NYHA Class IV heart failure
  • Adherence to medication and guideline-directed standard of care for established CV condition
  • Requested dose is at least 1.7 mg weekly
  • Will be used as adjunct to reduced calorie diet (≥ 500 kcal/day) and ≥ 150 min/week activity
  • Failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • No sustained increase in resting heart rate
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Reduction of ≥ 5% in body weight from baseline
  • Reduction of ≥ 3% body weight from baseline WITH decrease in LDL or triglycerides
  • Reduction of ≥ 3% body weight from baseline WITH decrease in waist circumference
  • Reduction of ≥ 3% body weight from baseline WITH decrease in blood pressure

Documentation to bring

  • Completed prior authorization request form
  • Chart notes documenting established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD with qualifying criteria)
  • HbA1c lab result within past 12 months (must be < 6.5%)
  • Documentation of current body weight / BMI (≥ 27 kg/m2)
  • Documentation of current guideline-directed standard of care medications for CV condition, or clinical reason GDMT is not appropriate
  • Documentation of failure, contraindication, or intolerance to three generic equivalents for at least 3 months each
  • Prescriber attestation that patient does not have type 1 or type 2 diabetes
  • Prescriber attestation that patient does not have NYHA Class IV heart failure
  • For renewal: chart notes documenting ≥ 5% body weight reduction OR ≥ 3% reduction with qualifying secondary benefit
  • For renewal: lab values confirming safe continued use
  • For renewal: supporting clinical documentation of adherence

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: At renewal, patient must have achieved and maintained ONE of: (1) ≥ 5% reduction in body weight from baseline, OR (2) ≥ 3% body weight reduction from baseline WITH at least one of: decrease in LDL or triglycerides, decrease in waist circumference, or decrease in blood pressure. Also requires continued adherence to medication and guideline-directed standard of care for established CV condition. Minimum dose of 1.7 mg weekly required at renewal. HbA1c < 6.5% and absence of T1DM/T2DM are re-verified at continuation. GDMT requirement is re-verified at continuation (adherence required). Note: brand-specific criteria (3 generic equivalent failures) are also re-checked at renewal.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Type 2 diabetes (gestational diabetes is excluded from this restriction)
  • NYHA Class IV heart failure
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior serious hypersensitivity reaction to semaglutide
  • Concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, tirzepatide)
  • Chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • Severe gastroparesis
  • Sustained increase in resting heart rate (continuation only)
  • Pregnancy
  • Type 1 diabetes

Policy note: This PCG applies to Commercial and/or Marketplace plans. It does NOT apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plans. Brand-specific criteria require failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each. Qualifying PAD includes: (1) intermittent claudication with ABI < 0.85 at rest, (2) peripheral arterial revascularization procedure, or (3) amputation due to atherosclerotic disease. GDMT examples listed include lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, and angiotensin receptor neprilysin inhibitor (ARNI). Manufacturer samples/assistance not accepted for continuation of therapy. Initial approval is 6 months or end of plan year; continuation is 12 months or end of plan year. HbA1c lookback period is 12 months.

Policy effective May 16, 2024 · verified June 2, 2026 · source: BCBS Arizona ACA Marketplace prior authorization policy

Open on its own page →

Questions people ask
Does BCBS Arizona cover Wegovy?
Yes. BCBS Arizona covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with BCBS Arizona?
Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 6 months. Renewal: every 12 months.
What does BCBS Arizona require to renew Wegovy?
Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. At renewal, patient must have achieved and maintained ONE of: (1) ≥ 5% reduction in body weight from baseline, OR (2) ≥ 3% body weight reduction from baseline WITH at least one of: decrease in LDL or triglycerides, decrease in waist circumference, or decrease in blood pressure. Also requires continued adherence to medication and guideline-directed standard of care for established CV condition. Minimum dose of 1.7 mg weekly required at renewal. HbA1c < 6.5% and absence of T1DM/T2DM are re-verified at continuation. GDMT requirement is re-verified at continuation (adherence required). Note: brand-specific criteria (3 generic equivalent failures) are also re-checked at renewal. Staying on a maintenance dose of at least 1.7 mg.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Arizona: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Molina Healthcare, BCBS Alabama, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Arizona's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.